Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden.
作者信息
Egger Michael E
机构信息
Hiram C. Polk, Jr., MD, Department of Surgery, University of Louisville, Louisville, KY, USA.
出版信息
Ann Transl Med. 2023 Aug 30;11(10):371. doi: 10.21037/atm-23-597. Epub 2023 Mar 3.
Abstract
摘要
相似文献
1
Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden.识别可能从辅助治疗中获益的高危IIIA期皮肤黑色素瘤患者：微转移肿瘤负荷的重要性。
Ann Transl Med. 2023 Aug 30;11(10):371. doi: 10.21037/atm-23-597. Epub 2023 Mar 3.
2
Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.国际多中心研究中早期黑色素瘤微转移的临床结果和风险分层：对美国癌症联合委员会 IIIA 疾病管理的影响。
J Clin Oncol. 2022 Dec 1;40(34):3940-3951. doi: 10.1200/JCO.21.02488. Epub 2022 Jul 18.
3
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.辅助达布拉非尼联合曲美替尼对比安慰剂治疗 BRAF 突变型 III 期黑色素瘤患者（COMBI-AD）：一项随机、III 期临床试验的探索性生物标志物分析。
Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30.
4
Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival.IIIa期黑色素瘤及多个阳性淋巴结对生存的影响。
J Am Coll Surg. 2021 Apr;232(4):517-524.e1. doi: 10.1016/j.jamcollsurg.2020.11.015. Epub 2020 Dec 13.
5
Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma.现在治疗还是稍后治疗：ⅢA期黑色素瘤切除术后辅助治疗的比较效果
J Am Coll Surg. 2022 Apr 1;234(4):521-528. doi: 10.1097/XCS.0000000000000088.
6
Recent advances in the care of the patient with malignant melanoma.恶性黑色素瘤患者护理的最新进展。
Ann Surg. 1997 Jan;225(1):1-14. doi: 10.1097/00000658-199701000-00001.
7
Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.可手术黑色素瘤：筛查、预后评估以及辅助和新辅助治疗
Am Soc Clin Oncol Educ Book. 2017;37:651-660. doi: 10.1200/EDBK_174930.
8
Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma.早期黑色素瘤切除患者的真实世界复发率及经济负担
Dermatol Ther (Heidelb). 2020 Oct;10(5):985-999. doi: 10.1007/s13555-020-00404-9. Epub 2020 Jun 16.
9
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.TMB 和 BRAF 突变状态是辅助抗 PD-1 治疗的高危黑色素瘤患者的独立预测因素。
J Cancer Res Clin Oncol. 2023 Feb;149(2):833-840. doi: 10.1007/s00432-022-03939-w. Epub 2022 Feb 22.
10
Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.澳大利亚高风险可切除黑色素瘤的治疗：现状与实践。
Australas J Dermatol. 2020 Aug;61(3):203-209. doi: 10.1111/ajd.13309. Epub 2020 May 13.
本文引用的文献
1
Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.国际多中心研究中早期黑色素瘤微转移的临床结果和风险分层：对美国癌症联合委员会 IIIA 疾病管理的影响。
J Clin Oncol. 2022 Dec 1;40(34):3940-3951. doi: 10.1200/JCO.21.02488. Epub 2022 Jul 18.
2
A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma.基于人群的第 8 版 UICC/AJCC TNM 分期系统在皮肤黑色素瘤中的验证研究。
BMC Cancer. 2022 Jul 1;22(1):720. doi: 10.1186/s12885-022-09781-0.
3
Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival.IIIa期黑色素瘤及多个阳性淋巴结对生存的影响。
J Am Coll Surg. 2021 Apr;232(4):517-524.e1. doi: 10.1016/j.jamcollsurg.2020.11.015. Epub 2020 Dec 13.
4
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.帕博利珠单抗辅助治疗与安慰剂对照用于 III 期黑色素瘤完全切除术后患者的随机、双盲、III 期临床试验
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
5
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.黑色素瘤分期：美国癌症联合委员会第八版癌症分期手册中基于证据的变化。
CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.
6
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.纳武利尤单抗辅助治疗与伊匹单抗用于切除的 III 期或 IV 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
7
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
8
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.黑色素瘤前哨淋巴结转移的完全解剖或观察
N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.
9
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.前哨淋巴结活检阳性黑色素瘤患者完全淋巴结清扫与不清扫（DeCOG-SLT）：一项多中心、随机、III 期临床试验。
Lancet Oncol. 2016 Jun;17(6):757-767. doi: 10.1016/S1470-2045(16)00141-8. Epub 2016 May 5.
10
Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma.黑色素瘤前哨淋巴结微转移瘤负荷测量的比较。
J Am Coll Surg. 2014 Apr;218(4):519-28. doi: 10.1016/j.jamcollsurg.2013.12.014. Epub 2013 Dec 21.
Zotero 插件